IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

Thu, 01st Oct 2020 06:40

Avacta Group PLC - Wetherby, England-based pre-clinical stage biotechnology company - Launches bead-assisted mass spectrometry, or BAMS, SARS-CoV-2 virus test. "The BAMS assay uses the Affimer reagents specific to the SARS-CoV-2 virus to capture the virus spike protein from the sample for rapid detection by mass spectrometry, using the installed base of these instruments in hospitals," Avacta says. Adds that one thousand samples per day can be analysed by a single technician using BAMS.

Current stock price: 155.00 pence, up 11% on Wednesday.

Year-to-date change: up sharply from 17.25p

By Eric Cunha; ericcunha@alliancenews.com

Related Shares

More News

23 May 2024 21:25

TRADING UPDATES: Windward wins deal; Kodal progresses at Bougouni

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

23 May 2024 12:09

Avacta reports further progress in chemotherapy trial

(Sharecast News) - Avacta Group announced the successful completion of the first cohort and the start of dosing for three patients in the second cohor...

7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

1 May 2024 11:53

IN BRIEF: Avacta picks Christina Coughlin to replace long-serving CEO

Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to ...

30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: